手术后胰岛素抵抗和肠道微生物群:机制和研究进展
Feng Lin1,2,3, Minzhi Sun1,2,3, Xiao Yuan1,2
1Department of General Surgery, The First Affiliated Hospital of Anhui Medical University. Hefei 230022, Anhui, China.
Microbiome research reports
|October 24, 2025
概括
手术后胰岛素耐药性 (PIR) 与肠道细菌有关. 调节肠道微生物组可能为管理PIR和改善患者康复提供新的策略.
科学领域:
- 代谢医学是一种代谢医学.
- 微生物组研究 微生物组研究
- 外科手术的结果
背景情况:
- 手术后胰岛素抵抗 (PIR) 是一个常见的代谢问题,影响患者的康复.
- 新兴研究强调了肠道微生物群和PIR之间的重要联系.
- 肠道微生物群落可能在调节胰岛素敏感性方面发挥作用.
研究的目的:
- 审查有关PIR和肠道微生物群之间的关系的当前文献.
- 探索肠道微生物群影响PIR的机制.
- 总结一下最近在理解这种相互作用方面的进展.
主要方法:
- 综合的文学综合. 综合的文学综合.
- 对研究肠道微生物群-PIR轴的研究进行分析.
- 对拟议的机械路径进行审查.
主要成果:
- 肠道微生物群与PIR的发展和进展密切相关.
- 机制包括微生物代谢物的影响,如内毒素,SCFA和BCAA.
- 肠道微生物的组成和功能是PIR的关键因素.
结论:
- 肠道微生物群是术后胰岛素抵抗的一个关键因素.
- 针对微生物组为PIR干预提供了一个有希望的途径.
- 进一步的研究可以为基于微生物组的策略提供信息,以改善手术结果.
相关概念视频
Glucagon-like Receptor Agonists
840
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
840
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
522
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
522
Oral Hypoglycemic Agents: Biguanides and Glitazones
582
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
582
Chronic Pancreatitis II: Collaborative Care
311
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
311
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
245
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
245
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K


